Cargando…
Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer
Differentiating the irinotecan dose on the basis of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotype improves the pathologic complete response (pCR) rate. In this study, we further investigated preoperative irinotecan combined with capecitabine-based chemoradiotherapy for locall...
Autores principales: | Zhu, Ji, Liu, Anwen, Sun, Xinchen, Liu, Luying, Zhu, Yaqun, Zhang, Tao, Jia, Jianhui, Tan, Shisheng, Wu, Junxin, Wang, Xin, Zhou, Juying, Yang, Jialin, Zhang, Chen, Zhang, Hongyan, Zhao, Yuanyuan, Cai, Gang, Zhang, Wei, Xia, Fan, Wan, Juefeng, Zhang, Hui, Shen, Lijun, Cai, SanJun, Zhang, Zhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768334/ https://www.ncbi.nlm.nih.gov/pubmed/33119477 http://dx.doi.org/10.1200/JCO.20.01932 |
Ejemplares similares
-
An expansion study of genotype-driven weekly irinotecan and capecitabine in combination with neoadjuvant radiotherapy for locally advanced rectal cancer with UGT1A1 *1*1 genotype
por: Guan, Yun, et al.
Publicado: (2019) -
CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer
por: Cai, Gang, et al.
Publicado: (2015) -
Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations
por: Gollins, Simon, et al.
Publicado: (2017) -
Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen
por: Zhu, Xiaoqin, et al.
Publicado: (2021) -
Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1(*)6 or UGT1A1(*)28
por: Tian, Chuan, et al.
Publicado: (2018)